This book presents the state of the art of biostatistical methods and their applications in clinical oncology. Many methodologies established today in biostatistics have been brought about through its applications to the design and analysis of oncology clinical studies. This field of oncology, now in the midst of evolution owing to rapid advances in biotechnologies and cancer genomics, is becoming one of the most promising disease fields in the shift toward personalized medicine. Modern developments of diagnosis and therapeutics of cancer have also been continuously fueled by recent progress in establishing the infrastructure for conducting more complex, large-scale clinical trials and observational studies. The field of cancer clinical studies therefore will continue to provide many new statistical challenges that warrant further progress in the methodology and practice of biostatistics. This book provides a systematic coverage of various stages of cancer clinical studies. Topics from modern cancer clinical trials include phase I clinical trials for combination therapies, exploratory phase II trials with multiple endpoints/treatments, and confirmative biomarker-based phase III trials with interim monitoring and adaptation. It also covers important areas of cancer screening, prognostic analysis, and the analysis of large-scale molecular data in the era of big data.

Presents the state of the art of biostatistics in clinical oncology, covering various topics from design and analysis of modern clinical trials, disease screening, prognostic analysis, and analysis of large-scale molecular data Is written by experts in biostatistical methodology and practice in cancer clinical studies Sets forth an effective balance between biostatistical methodology and practice Includes supplementary material: sn.pub/extras

Autorentext
Shigeyuki Matsui, Professor, Department of Biostatistics, Nagoya University Graduate School of Medicine, smatsui@med.nagoya-u.ac.jp, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
John Crowley, President and CEO, Cancer Research and Biostatistics, johnc@crab.org, 1730 Minor Ave STE 1900 Seattle, WA 98101-1468

Inhalt

1. Phase I clinical trials.- 2. Phase II clinical trials.- 3. Phase III clinical trials.- 4. Evaluation of surrogate endpoints.- 5. Disease Screening/development of diagnosis.- 6. Analysis of omics data (genomic signature developments etc).- 7. Causal inference in clinical trials and observational studies.